Skip to main content
HWAIL PHARM. CO., LTD logo

HWAIL PHARM. CO., LTD — Investor Relations & Filings

Ticker · 061250 ISIN · KR7061250007 KO Manufacturing
Open in API
Filings indexed 273 across all filing types
Latest filing 2025-03-06 AGM Information
Country KR South Korea
Listing KO 061250

About HWAIL PHARM. CO., LTD

http://www.hwail.com/

Hwail Pharm. Co., Ltd. is a pharmaceutical company that specializes in the research, development, manufacturing, and distribution of Active Pharmaceutical Ingredients (APIs). The company also provides a range of finished drug formulations, including generic and patented medications, as well as functional health products. A core focus of the organization is maintaining high standards through continuous R&D investment and rigorous quality control processes to develop and produce its pharmaceutical products.

Recent filings

Filing Released Lang Actions
주주총회집중일개최사유신고
AGM Information Classification · 95% confidence The document is a formal regulatory filing submitted by Hwail Pharmaceutical regarding the scheduling of their Annual General Meeting (AGM) on a 'concentrated date' (a date when many companies hold their AGMs). It explains the reasoning for choosing this date despite regulatory requests for dispersion. Since this is a specific regulatory disclosure regarding meeting logistics and does not contain the actual AGM presentation materials, voting results, or proxy statements, it falls under the general regulatory filing category.
2025-03-06 Korean
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a 'Notice of Annual General Meeting' (주주총회소집공고) for Hwail Pharmaceutical Co., Ltd. It includes the meeting date, location, agenda items (such as approval of financial statements, election of directors, and remuneration limits), and detailed management information including financial statements and board activity reports. This document is a formal proxy statement and meeting notice sent to shareholders to solicit votes for the upcoming AGM.
2025-03-06 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 100% confidence The document is a regulatory filing from a Korean company (Hwa-il Pharm) announcing a significant change in financial results (revenue or profit/loss structure exceeding 15% for large corporations or 30% for others). This is a standard disclosure requirement in the Korean stock market (KRX) for material financial changes. Since it provides the initial announcement of financial performance figures before the final audit, it falls under the 'Earnings Release' category as it reports key financial highlights. FY 2024
2025-02-03 Korean
전환가액의조정
Capital/Financing Update Classification · 100% confidence The document is a formal regulatory filing from a Korean company (Hwa-il Pharm) regarding the adjustment of the conversion price of convertible bonds due to a decline in market price. This type of disclosure is a standard corporate action related to capital structure and financing instruments. Among the provided categories, 'CAP' (Capital/Financing Update) is the most accurate fit as it covers updates on financing activities and capital structure changes.
2025-01-20 Korean
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 95% confidence The document is a short regulatory announcement regarding the setting of a record date and the closure of the shareholder register for the purpose of holding an upcoming Annual General Meeting (AGM). It does not contain the full proxy materials or the meeting presentation itself, but rather serves as a formal regulatory notice of the procedural steps for the meeting. Given it is a standard regulatory notification regarding corporate governance procedures, it fits best under the RNS category.
2024-12-13 Korean
분기보고서 (2024.09)
Interim / Quarterly Report Classification · 100% confidence The document is a '분기보고서' (Quarterly Report) for HWAIL PHARMACEUTICAL CO., LTD. covering the period from January 1, 2024, to September 30, 2024. It contains detailed financial and operational information, including company overview, management changes, capital structure, and business activities, which is characteristic of a formal quarterly financial report filed with the Korean regulatory authorities (Financial Supervisory Service/Korea Exchange). 9M 2024
2024-11-14 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.